734 related articles for article (PubMed ID: 21821703)
1. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
2. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
3. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.
Linn YC; Lau SK; Liu BH; Ng LH; Yong HX; Hui KM
Immunology; 2009 Mar; 126(3):423-35. PubMed ID: 18778291
[TBL] [Abstract][Full Text] [Related]
5. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
7. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
9. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
11. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
[TBL] [Abstract][Full Text] [Related]
12. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
13. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.
Campos C; López N; Pera A; Gordillo JJ; Hassouneh F; Tarazona R; Solana R
Biogerontology; 2015 Oct; 16(5):671-83. PubMed ID: 25991472
[TBL] [Abstract][Full Text] [Related]
14. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
15. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.
Mehta BA; Schmidt-Wolf IG; Weissman IL; Negrin RS
Blood; 1995 Nov; 86(9):3493-9. PubMed ID: 7579455
[TBL] [Abstract][Full Text] [Related]
16. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.
Magri G; Muntasell A; Romo N; Sáez-Borderías A; Pende D; Geraghty DE; Hengel H; Angulo A; Moretta A; López-Botet M
Blood; 2011 Jan; 117(3):848-56. PubMed ID: 21030563
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
18. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
19. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
